Medtrum
Shanghai-based diabetes medical device developer (founded 2008) building an integrated AID ecosystem — world's smallest 200U and first 300U tubeless patch pumps, CGM sensors, and the proprietary APGO algorithm — for insulin-dependent patients across 50+ countries via direct subsidiaries and insurance-covered prescription channels.
- Company typePrivate
- Founded2008
- HeadquartersShanghai, China
- Headcount101–250
- GTM typeB2C
- OfferingHardware or Manufacturing
What Medtrum does
Medtrum is a Shanghai-based diabetes medical device developer founded in 2008 by Scott Yang, focused exclusively on building an integrated Automated Insulin Delivery (AID) ecosystem for insulin-dependent patients. The company's core technology stack comprises the TouchCare Nano tubeless patch pump (the world's smallest 200U pump at 13.8g and the first 300U tubeless pump), the TouchCare Nano CGM (14-day wear, calibration-free, 2-minute readings), and the proprietary APGO (Artificial Pancreas GO) self-learning algorithm that integrates both devices into a hybrid closed-loop AID system with Auto Meal Handling and Predictive Low Glucose Suspend features. This vertical integration of pump, CGM, and algorithm in-house is rare in the diabetes device industry and underpins Medtrum's competitive position.
The business model combines upfront hardware revenue from pump and CGM sales with high-margin recurring revenue from consumables — 14-day CGM sensor replacements and 3-day pump reservoir changes — sold through a multi-channel GTM spanning direct-to-consumer country websites, HCP prescription pathways, and country-specific medical insurance coverage in over 20 European countries. Distribution is executed through wholly-owned subsidiaries in 10+ European markets (UK, Germany, France, Netherlands, Denmark, Sweden, Norway, Austria) plus China, Hong Kong, and Turkey, with regulatory approvals secured in Europe and Brazil and products available in 50+ countries. Marketing combines clinical evidence publication at conferences (ATTD, SFD), patient testimonial content (Medtrum Marvels), and a connected-care software suite (EasyPatch, EasyTouch, EasySense, EasyFollow, EasyView, Apple Watch integration) that extends the hardware business into a sticky ecosystem for patients, caregivers, and healthcare professionals.
Founded as a private, founder-controlled company with a $29.06M funding round closed in December 2018, Medtrum has 101-250 employees and continues to pursue geographic and product expansion, with the November 2025 300U pump launch and March 2026 Auto Meal Handling feature representing its most recent product milestones. The company demonstrates clinical credibility through published outcomes including a 12.51 percentage point Time in Range improvement and 0.65% HbA1c reduction in real-world studies.
Medtrum firmographics
Firmographics- Name
- Medtrum
- Legal name
- Medtrum Technologies Inc.
- Website
- https://medtrum.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Shanghai-based diabetes medical device developer (founded 2008) building an integrated AID ecosystem — world's smallest 200U and first 300U tubeless patch pumps, CGM sensors, and the proprietary APGO algorithm — for insulin-dependent patients across 50+ countries via direct subsidiaries and insurance-covered prescription channels.
- Ownership category
- akta.pro rank
Medtrum industry classification
Industry- Product category
- Diabetes Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
- akta.pro secondary industries
- Patch Pumps & Wearable Insulin Delivery (HLAHAHAC), Insulin Pumps & Patch Pumps (HLAHAIAG), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL)
Keywords
Where Medtrum is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices10 records
Markets served
Medtrum business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Hardware Devices Sales: Sale of medical devices including TouchCare Nano insulin pumps, CGM sensors, and transmitters. Products are available by prescription and covered by medical insurance in over 20 European countries.
- Consumables and Supplies: Recurring revenue from consumables including sensor replacements (every 14 days), patch pump reservoir changes (every 3 days), and accessories. The modular design allows sensors to be replaced separately from transmitters, creating ongoing consumable revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | TouchCare Nano Hybrid Closed-Loop AID System - insurance covered in Europe |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Medtrum product offering
Product offeringCore offering
Medtrum designs, develops, manufactures, and sells an integrated diabetes management ecosystem comprising a tubeless patch insulin pump (TouchCare Nano Pump, 200U and 300U), a 14-day continuous glucose monitor (TouchCare Nano CGM), and a hybrid closed-loop automated insulin delivery system (TouchCare Nano System) powered by its proprietary APGO self-learning algorithm. The portfolio is complemented by mobile applications (EasyPatch, EasyTouch, EasySense, EasyFollow) and a cloud-based clinician reporting platform (EasyView), sold primarily by prescription to insulin-dependent patients and reimbursed by medical insurance in over 20 European countries.
Product overview
Medtrum offers a comprehensive diabetes management ecosystem centered on three core products: the TouchCare Nano Insulin Pump (tubeless patch pump in 200U and 300U capacities), TouchCare Nano CGM (14-day continuous glucose monitor), and the TouchCare Nano System (hybrid closed-loop automated insulin delivery integrating both via the proprietary APGO algorithm). These core devices are complemented by a suite of mobile applications including EasyPatch (smartphone pump control), EasyTouch (PDM companion app), EasySense (standalone CGM app), EasyFollow (data sharing with caregivers), and EasyView (cloud-based professional reporting). The portfolio represents a vertically integrated ecosystem where all components are developed in-house, enabling seamless interoperability between pump, CGM, and AI-powered automation features like Auto Meal Handling. Products are available in over 50 countries across Europe, Asia, and other regions.
Differentiator
Problem solved
Functional benefit
Brands
- TouchCare: Brand name for Medtrum's diabetes management products including TouchCare Nano CGM, TouchCare Nano Pump, and TouchCare Nano System (AID system)
- TouchCare Nano CGM
- TouchCare Nano Pump
- TouchCare Nano System
- EasyPatch App
- EasyTouch App
- EasySense App
- EasyFollow App
- EasyView
- APGO
- TouchCare S9 CGM
Quantifiable outcome
- Time in Range (TIR) increased from 59.08% to 71.59% (12.51 percentage point improvement) after 3 months of Medtrum A8 TouchCare use in adults with Type 1 diabetes
- +4 more outcomes
Companies that use Medtrum
Customer profileNamed customers9 records
Segments5 records
Ideal customer profiles3 records
Medtrum technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability4 records
Feature6 records
Medtrum partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bauerfeind Diabetes Expert TeamcoreBauerfeind's diabetes expert team in Croatia provided hospital training and ongoing support for parents of children using Medtrum Nano pump. The representative demonstrated extensive diabetes knowledge and was available 24/7 for assistance, significantly helping the family learn to use the pump system effectively.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Medtrum competitors and assessment
Company assessmentEmerging players
- CamDiab: CamDiab provides the CamAPS FX AID algorithm used in Ypsomed's mylife Loop and other partner systems. Comparable as an algorithm-only AID competitor to Medtrum's APGO algorithm offering, particularly in European clinical settings.
- SOOIL Development: SOOIL is a Korean manufacturer of the DANA Diabecare patch pump line, comparable to Medtrum as a patch pump specialist. Smaller global footprint but a direct competitor in Asian and select European markets.
- Diabeloop: Diabeloop develops AID algorithms (DBLG1) that integrate with multiple pump and CGM partners. Comparable as an algorithm-focused diabetes technology peer that competes with Medtrum's APGO algorithm offering.
Broad incumbents
- Roche Diabetes Care: Roche offers insulin pumps (Accu-Chek) and integrated diabetes management solutions across European markets. Comparable as a broad incumbent in the European diabetes device market where Medtrum competes for reimbursement.
- Dexcom: Dexcom is the CGM market leader (G7) and partners with multiple AID pump makers including Tandem and Insulet. Comparable as a CGM technology peer with overlapping integration relationships that compete with Medtrum's integrated CGM.
- Abbott Diabetes Care: Abbott's FreeStyle Libre 3 dominates the CGM market globally and is increasingly integrating with AID systems. Comparable as a CGM technology and consumer-scale diabetes device competitor to Medtrum's TouchCare Nano CGM.
- Medtronic Diabetes: Medtronic is the incumbent AID player with MiniMed 780G and integrated CGM (Guardian 4). Comparable as a vertically integrated AID competitor with broad global reach and significantly larger installed base than Medtrum.
Direct peers
- Insulet Corporation: Insulet is the market leader in tubeless patch pumps with Omnipod 5, the dominant tubeless AID system globally. Directly comparable to Medtrum as both target the same tubeless patch pump + AID customer segment with similar smartphone-integration strategies.
- Tandem Diabetes Care: Tandem offers the t:slim X2 pump with Control-IQ AID algorithm, directly competing with Medtrum's hybrid closed-loop AID system for Type 1 diabetes patients, particularly in the US and European markets.
- Ypsomed: Ypsomed offers the mylife Loop AID system combining YpsoPump with CamDiab algorithm, directly competing in European markets with Medtrum. Both target similar European reimbursement pathways and Type 1 diabetes patient segments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Medtrum social profiles
Digital presenceMedtrum financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medtrum leadership team
Management profileNumber of profiles
Profiles2 records
Medtrum subsidiaries and ownership
Company hierarchySubsidiaries9 records
Medtrum funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medtrum M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medtrum
What does Medtrum do?
Medtrum designs, develops, manufactures, and sells an integrated diabetes management ecosystem comprising a tubeless patch insulin pump (TouchCare Nano Pump, 200U and 300U), a 14-day continuous glucose monitor (TouchCare Nano CGM), and a hybrid closed-loop automated insulin delivery system (TouchCare Nano System) powered by its proprietary APGO self-learning algorithm. The portfolio is complemented by mobile applications (EasyPatch, EasyTouch, EasySense, EasyFollow) and a cloud-based clinician reporting platform (EasyView), sold primarily by prescription to insulin-dependent patients and reimbursed by medical insurance in over 20 European countries.
Is Medtrum a public or private company?
Medtrum is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Medtrum founded?
Medtrum was founded in 2008. It employs 101 to 250 people.
Where is Medtrum based?
Medtrum is headquartered in Shanghai, China, in the Asia region.
How does Medtrum make money?
Two revenue lines are on record. Hardware Devices Sales are the primary driver. The others are consumables and Supplies.
Who are Medtrum's main competitors?
Emerging players on record are CamDiab, SOOIL Development and Diabeloop. Broad incumbents are Roche Diabetes Care, Dexcom, Abbott Diabetes Care and Medtronic Diabetes. Direct peers are Insulet Corporation, Tandem Diabetes Care and Ypsomed.
Does Medtrum have an API?
No public API is recorded for Medtrum.
What industry is Medtrum in?
Medtrum's product category is Diabetes Medical Devices. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAHAC, Patch Pumps & Wearable Insulin Delivery. Its NAICS code is 334510 and its SIC code is 3841.